Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
12 août 2024 16h15 HE
|
Biora Therapeutics, Inc.
Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan Company secures up to $16M funding from...
Biora Therapeutics Announces Funding Agreement with Existing Investors
12 août 2024 16h05 HE
|
Biora Therapeutics, Inc.
$16 million multiple-draw facility to be used as a bridge to anticipated pharma partnership
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
08 août 2024 16h30 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and...
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
06 août 2024 08h00 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate...
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
18 juil. 2024 08h00 HE
|
Biora Therapeutics, Inc.
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired.
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
08 juil. 2024 08h00 HE
|
Biora Therapeutics, Inc.
Event to highlight results from the clinical trial of BT-600, an orally administered drug-device combination in development for ulcerative colitis.
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
01 juil. 2024 08h00 HE
|
Biora Therapeutics, Inc.
BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ability to deliver therapeutics directly to the colon
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
11 juin 2024 08h00 HE
|
Biora Therapeutics, Inc.
Biora will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the conference on June 19, 2024.
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
20 mai 2024 08h00 HE
|
Biora Therapeutics, Inc.
Four device performance studies demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions.
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
15 mai 2024 16h05 HE
|
Biora Therapeutics, Inc.
Management will host conference call and webcast today, May 15, 2024, at 4:30 PM Eastern / 1:30 PM Pacific.